Changes in Beta-Cell Function during Dapagliflozin Therapy in Combination with Exenatide in Type 2 Diabetes Patients (T2D)

被引：0
|
作者：
Defronzo, Ralph A.
Baskoy, Gozde
Triplitt, Curtis L.
Cersosimo, Eugenio
Solis-Herrera, Carolina
Adams, John M., II
Hansis-Diarte, Andrea A.
Gastaldelli, Amalia
Chavez, Alberto
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-1550-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1550-P
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes
    Karasik, Avraham
    Charbonnel, Bernard
    Liu, Ji
    Wu, Mei
    Meehan, Alan
    Meininger, Gary
    DIABETES, 2006, 55 : A119 - A120
  • [32] Clinical Characteristics and Outcomes in Patients with Type 2 Diabetes (T2D) Adding Insulin Glargine to Exenatide or Exenatide to Insulin Glargine in a US Managed Care Setting
    Levin, Philip
    Wei, Wenhui
    Wang, Li
    Damon, Douglas
    Baser, Onur
    DIABETES, 2011, 60 : A266 - A266
  • [33] Empagliflozin Improves Beta-Cell Function Independently of Glucose Toxicity in Patients with Type 2 Diabetes
    Thirumathyam, Roopameera
    Richter, Erik A.
    Goetze, Jens Peter
    Madsen, Per L.
    Holst, Jens J.
    Madsbad, Sten, Sr.
    Jorgensen, Nils B.
    DIABETES, 2022, 71
  • [34] Continuous Subcutaneous Insulin Infusion Therapy Increased Beta-Cell Function for One Year in Type 2 Diabetes Patients
    Hong, Eun Shil
    Choi, Soo Bong
    An, Hyun Ju
    Noh, Yun H.
    DIABETES, 2017, 66 : A279 - A279
  • [35] Safety and Efficacy of Linagliptin and Basal Insulin Combination Therapy in Elderly Patients (age ≥70 years) with Type 2 Diabetes (T2D)
    Woerle, H. J.
    Neubacher, D.
    Patel, S.
    von Eynatten, M.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2013, 61 : S31 - S32
  • [36] Restoration of beta-cell function following biliopancreatic diversion (BPD) in patients with type 2 diabetes
    Camerini, G
    Briatore, L
    Salani, B
    Marinari, GM
    Papadia, FS
    Murelli, F
    Adami, GF
    Scopinaro, N
    OBESITY SURGERY, 2006, 16 (04) : 413 - 413
  • [37] Sitagliptin improved beta-cell function in patients with type 2 diabetes (T2DM): A model-based analysis
    Xu, Lei
    Man, Chiara Dalla
    Cobelli, Claudio
    Williams-Herman, Debora
    Meininger, Gary
    Khatami, Hootan
    Stein, Peter
    DIABETES, 2006, 55 : A466 - A466
  • [38] Changes in lipid profiles of patients with type 2 diabetes mellitus on dapagliflozin therapy
    Hardy, E.
    Ptaszynska, A.
    de Bruin, T. W. A.
    Johnsson, E.
    Parikh, S. J.
    List, J. F.
    DIABETOLOGIA, 2013, 56 : S379 - S379
  • [39] Effect of dapagliflozin on renal haemodynamics in hyperfiltering T2D patients
    Cersosimo, Eugenio
    YueJuan, Qin
    Baskoy, Gozde
    Chavez, Alberto
    Barkhordarian, Maryam
    Hansis-Diarte, Andrea
    Triplitt, Curtis
    DeFronzo, Ralph A.
    DIABETES OBESITY & METABOLISM, 2025, 27 (02): : 944 - 952
  • [40] Glycemic Control and Adherence to Basal Insulin Therapy in Taiwanese Patients with Type 2 Diabetes (T2D)
    Chien, Ming-Nan
    Chen, Yen-Ling
    Hung, Yi-Jen
    Wang, Shu-Yi
    Lu, Wen-Tsung
    Chen, Chih-Hung
    Lin, Ching-Ling
    Huang, Tze-Pao
    Tsai, Ming-Han
    Tseng, Wei-Kung
    Wu, Ta-Jen
    Ho, Cheng
    Lin, Wen-Yu
    Chen, Bill
    Chuang, Lee-Ming
    DIABETES, 2014, 63 : A600 - A600
12345